PYC pyc therapeutics limited

1.89%

$1.30

Kidney Cyst drug would be a US$10 billion p.a. blockbuster, page-6

First 6 Last

Share
Profile

Follow
Timbo57

136 Posts.

42

18/10/24

10:16

Post #: 76182134
Share

Originally posted by Ladytradr: ↑

On another thread I have pointed out that CSL is on a current price to earning multiple of 60x

vaccines is obviously a very big global market, but the margins look much slimmer based on CSL gross revenues/profit.

From what I can gather, assuming trials for the kidney drug do come up ‘trumps’ (can we please find another word for such successes?) the kidney drug could be in the market as early as 2030 (and do please correct me if I’m wrong)

If we are sitting here around 2028/2029 Medicine trial programs that are looking like the drug will be commercially successful (a bit like RP 11 is looking right now), what would be a fair prospective price earnings multiple?

I’m thinking only 10x ,,, because investors may not initially believe the potential margins and gross market revenues/penetration forcast.

assuming above, I arrive at the conclusion now that this kidney drug (after the most important successful trials ticked off) could be valued on the Australian market at ~$100 billion valuation by 2029. (and that ignoring the contribution of eye drugs etc)

i think that currently equates to $20 per share on pre consolidation 20 cents ptice (and $200 per share post consolidation)

a great deal of water to pass under the bridge over the next 4 years, but I will certainly not be losing sight of that target price.

call me a crazy optimist if you like, but show me where I am making any fundamentally wrong assumptions please?

- the drug has been tested on lab grown human diseased tissue and also donated amputates patient kidneys (people going onto full time dialysis) and it must have indicated it works.
- toxicity tests have also been trialled on primates at materially higher volumes than would ever be injected into humans (and no evidence identified of issues)

so to date … the drug seems it should work on the human disease … there is no competition and and there is unlikely to be toxicity issues.

what else should we be looking out for in this process please Medicine Man et al?

Expand

If PYC were to apply the Priority Review Voucher to the kidney drug (PYC003), what impact would that have on timing to market? Does 2030 become 2029?

PYC Price at posting: 20.0¢ Sentiment: Buy Disclosure: Held
8 Upvote

1 Great analysis

Reply

Top Stories

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

SGQ

St George banks $5M from placement to ramp up Araxá Rare Earths Project

RNU

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

ASE

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

FTL

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

First 6 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.30		Change -0.025(1.89%)		Mkt cap ! $755.3M

Open	High	Low	Value	Volume
$1.32	$1.32	$1.30	$478.1K	365.3K

Buyers (Bids)

No.	Vol.	Price($)
1	2000	$1.29

Sellers (Offers)

Price($)	Vol.	No.
$1.32	10000	1

View Market Depth

No.	Vol.	Price($)
1	700	1.250
2	22000	1.220
2	2166	1.200
1	8474	1.180
1	6000	1.140

Price($)	Vol.	No.
1.320	10000	1
1.330	3633	1
1.340	9300	1
1.420	26097	2
1.425	25000	1

Last trade - 16.10pm 25/07/2025 (20 minute delay)

PYC (ASX) Chart

Kidney Cyst drug would be a US$10 billion p.a. blockbuster, page-6

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Kidney Cyst drug would be a US$10 billion p.a. blockbuster, page-6

Top Stories

Friday's HotCopper trends: Renascor concentrate, Larvotto raise | July 25

What is going on here? Watch out for DroneShield, Pure Hydrogen, and Nel ASA

Most investors will get this earnings season wrong. Will you?

St George banks $5M from placement to ramp up Araxá Rare Earths Project

Renascor produces graphite concentrate at Siviour, right on time to meet ex-China demand

Astute delivers high-grade lithium hits at Red Mountain

Rokeby, BHM, more: The 10 hot stocks HotCopper users watchlisted in Week 30

Firetail scoops up untested land around Excelsior – including juicy mineralisation target

ASX Market Close: Fading miners drag bourse as iron ore price slumps | July 25

Listen: HotCopper Wire Podcast 019 – Dreaming of the 9,000s

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News